Itau Unibanco Holding S.A. raised its place in AbbVie Inc. (NYSE:ABBV – Free Report) by 4.5% throughout the second quarter, in accordance with the corporate in its most up-to-date disclosure with the Securities & Trade Fee. The institutional investor owned 9,645 shares of the corporate’s inventory after shopping for a further 416 shares throughout the interval. Itau Unibanco Holding S.A.’s holdings in AbbVie had been value $1,654,000 as of its most up-to-date SEC submitting.
A number of different massive traders have additionally just lately added to or decreased their stakes in ABBV. Vermillion & White Wealth Administration Group LLC purchased a brand new stake in AbbVie throughout the 4th quarter value roughly $26,000. Fairway Wealth LLC purchased a brand new stake in shares of AbbVie throughout the second quarter value $26,000. Ridgewood Investments LLC acquired a brand new stake in shares of AbbVie within the second quarter valued at $27,000. In a position Wealth Administration LLC acquired a brand new stake in shares of AbbVie within the fourth quarter valued at $33,000. Lastly, IFS Advisors LLC purchased a brand new place in shares of AbbVie within the first quarter valued at about $36,000. 70.23% of the inventory is owned by institutional traders.
Wall Road Analyst Weigh In
Plenty of equities analysis analysts have commented on ABBV shares. HSBC raised shares of AbbVie from a “maintain” ranking to a “purchase” ranking and set a $185.00 value goal on the inventory in a report on Wednesday, June fifth. William Blair raised shares of AbbVie to a “strong-buy” ranking in a report on Friday, August thirtieth. Piper Sandler upped their value goal on AbbVie from $196.00 to $209.00 and gave the inventory an “obese” ranking in a report on Friday, August twenty third. Cantor Fitzgerald reissued an “obese” ranking and issued a $200.00 goal value on shares of AbbVie in a analysis be aware on Monday, August fifth. Lastly, Truist Monetary reaffirmed a “purchase” ranking and set a $210.00 value goal (up beforehand from $195.00) on shares of AbbVie in a analysis be aware on Friday, July twenty sixth. Two equities analysis analysts have rated the inventory with a maintain ranking, twelve have assigned a purchase ranking and two have given a powerful purchase ranking to the corporate’s inventory. In line with knowledge from MarketBeat, AbbVie at the moment has a consensus ranking of “Purchase” and a consensus value goal of $191.64.
Learn Our Newest Report on ABBV
Insiders Place Their Bets
In different information, Chairman Richard A. Gonzalez bought 66,500 shares of AbbVie inventory in a transaction dated Monday, August fifth. The inventory was bought at a mean value of $186.52, for a complete transaction of $12,403,580.00. Following the transaction, the chairman now owns 446,599 shares within the firm, valued at roughly $83,299,645.48. The transaction was disclosed in a doc filed with the Securities & Trade Fee, which is out there at the SEC web site. In associated information, Chairman Richard A. Gonzalez bought 66,500 shares of the agency’s inventory in a transaction on Monday, August fifth. The shares had been bought at a mean value of $186.52, for a complete transaction of $12,403,580.00. Following the sale, the chairman now immediately owns 446,599 shares within the firm, valued at $83,299,645.48. The sale was disclosed in a doc filed with the SEC, which is out there at this hyperlink. Additionally, Chairman Richard A. Gonzalez bought 282,845 shares of the inventory in a transaction dated Wednesday, July seventeenth. The inventory was bought at a mean value of $175.00, for a complete worth of $49,497,875.00. Following the transaction, the chairman now owns 513,099 shares of the corporate’s inventory, valued at roughly $89,792,325. The disclosure for this sale might be discovered right here. Company insiders personal 0.25% of the corporate’s inventory.
AbbVie Inventory Efficiency
Shares of ABBV inventory opened at $193.47 on Friday. The inventory has a market cap of $341.64 billion, a PE ratio of 57.41, a price-to-earnings-growth ratio of two.66 and a beta of 0.64. The inventory has a 50-day transferring common of $189.35 and a 200-day transferring common of $175.80. The corporate has a debt-to-equity ratio of 8.51, a present ratio of 0.81 and a fast ratio of 0.71. AbbVie Inc. has a one yr low of $135.85 and a one yr excessive of $199.95.
AbbVie (NYSE:ABBV – Get Free Report) final issued its earnings outcomes on Thursday, July twenty fifth. The corporate reported $2.65 EPS for the quarter, beating the consensus estimate of $2.57 by $0.08. AbbVie had a web margin of 9.71% and a return on fairness of 203.66%. The agency had income of $14.46 billion throughout the quarter, in comparison with the consensus estimate of $14.02 billion. Throughout the identical quarter within the prior yr, the agency earned $2.91 earnings per share. The enterprise’s quarterly income was up 4.3% on a year-over-year foundation. As a gaggle, sell-side analysts count on that AbbVie Inc. will submit 10.86 earnings per share for the present yr.
AbbVie Dividend Announcement
The agency additionally just lately declared a quarterly dividend, which will probably be paid on Friday, November fifteenth. Shareholders of document on Tuesday, October fifteenth will probably be issued a $1.55 dividend. The ex-dividend date is Tuesday, October fifteenth. This represents a $6.20 annualized dividend and a dividend yield of three.20%. AbbVie’s dividend payout ratio (DPR) is at the moment 183.98%.
About AbbVie
AbbVie Inc discovers, develops, manufactures, and sells prescription drugs worldwide. The corporate affords Humira, an injection for autoimmune and intestinal Behçet’s illnesses, and pyoderma gangrenosum; Skyrizi to deal with reasonable to extreme plaque psoriasis, psoriatic illness, and Crohn’s illness; Rinvoq to deal with rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn’s illness; Imbruvica for the remedy of grownup sufferers with blood cancers; Epkinly to deal with lymphoma; Elahere to deal with most cancers; and Venclexta/Venclyxto to deal with blood cancers.
Additional Studying
Obtain Information & Scores for AbbVie Every day – Enter your e-mail handle under to obtain a concise day by day abstract of the most recent information and analysts’ rankings for AbbVie and associated corporations with MarketBeat.com’s FREE day by day e-mail publication.